Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10697906 | 0.84 | QDPR (0.34) | QDPRPLG | |
| SCHEMBL1241881 | 0.81 | CYP2D6 (0.33) | — | |
| SCHEMBL8872933 | 0.78 | — | — | |
| SCHEMBL10460152 | 0.78 | — | — | |
| SCHEMBL28109507 | 0.78 | — | — | |
| SCHEMBL10922111 | 0.75 | QDPR (0.40) | QDPR | |
| SCHEMBL4824901 | 0.75 | PRMT3 (0.36) | — | |
| SCHEMBL20908872 | 0.75 | QDPR (0.38) | QDPRPLG | |
| SCHEMBL28409288 | 0.74 | — | — | |
| SCHEMBL28344652 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286973-A1 | PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2023-09-14 | — | — | US | claimed |
| CN-116675642-A | Preparation method of chiral aporphine alkaloid | 智简生物科技(上海)有限公司 | 2023-09-01 | — | — | CN | claimed |
| EP-4204417-A1 | PROTEIN SECRETION INHIBITORS | Kezar Life Sciences (US) | 2023-07-05 | — | — | EP | claimed |
| CN-116194455-A | Protein secretion inhibitor | 科智生命科学公司 | 2023-05-30 | — | — | CN | claimed |
| WO-2022047347-A1 | PROTEIN SECRETION INHIBITORS | KEZAR LIFE SCIENCES (US) | 2022-03-03 | — | — | WO | claimed |
| US-20230286973-A1 | PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2023-09-14 | — | — | US | disclosed |
| CN-116675642-A | Preparation method of chiral aporphine alkaloid | 智简生物科技(上海)有限公司 | 2023-09-01 | — | — | CN | disclosed |
| EP-4204417-A1 | PROTEIN SECRETION INHIBITORS | Kezar Life Sciences (US) | 2023-07-05 | — | — | EP | disclosed |
| CN-116194455-A | Protein secretion inhibitor | 科智生命科学公司 | 2023-05-30 | — | — | CN | disclosed |
| WO-2022047347-A1 | PROTEIN SECRETION INHIBITORS | KEZAR LIFE SCIENCES (US) | 2022-03-03 | — | — | WO | disclosed |
| EP-3284738-B1 | 5-AROMATIC ALKYNYL SUBSTITUTED BENZAMIDE COMPOUND AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND USE THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2020-11-25 | — | — | EP | disclosed |
| CN-107531633-B | 5-aromatic alkynyl substituted benzamide compound and preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2020-11-06 | — | — | CN | disclosed |
| CN-1128992-A | Therapeutic agents | KNORR CO LTD (DE) | 1996-08-14 | — | — | CN | disclosed |
| EP-0707570-A1 | ISOQUINOLINE DERIVATIVES AS THERAPEUTIC AGENTS | Knoll AG (DE) | 1996-04-24 | — | — | EP | disclosed |
| WO-1995021826-A1 | ANTIMALARIAL KORUPENSAMINES AND PHARMACEUTICAL COMPOSITIONS AND MEDICAL USES THEREOF | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1995-08-17 | — | — | WO | disclosed |
| US-5409938-A | A plant extracts having a naphthyl-tetrahydroisoquinolines group; a new drug treating malarial, parasiticides | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1995-04-25 | — | — | US | disclosed |
| WO-1995000489-A1 | ISOQUINOLINE DERIVATIVES AS THERAPEUTIC AGENTS | KNOLL AG (DE) | 1995-01-05 | — | — | WO | disclosed |
| EP-0598171-A1 | Nitrogen bridge tetrahydroisoquinolines | Anaquest, Inc. (US) | 1994-05-25 | — | — | EP | disclosed |
| US-5240939-A | Muscle relaxants | ANAQUEST, INC. (US) | 1993-08-31 | — | — | US | disclosed |
| US-4377652-A | PARTICLES DISPERSED IN A POLYMER BASED ON AN AROMATIC DIAMINE AND TRIMELLITIC ACID OR DERIVATIVE; DIELECTRICS; SUBSTRATES; PRINTED CIRCUITS | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1983-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286973-A1 | PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | QDPR 3251/4885PLG 2729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.